Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

GM Goodwin(Warneford Hospital), Peter Haddad(Greater Manchester Mental Health NHS Foundation Trust), I. Nicol Ferrier(Cumbria Northumberland Tyne and Wear NHS Foundation Trust), JK Aronson(Nuffield Health), TRH Barnes(Centre for Mental Health), Andrea Cipriani(Warneford Hospital), David Coghill(The University of Melbourne), Seena Fazel(Warneford Hospital), John Geddes(Warneford Hospital), Heinz Grunze(Christian Doppler Klinik), Emily A. Holmes(MRC Cognition and Brain Sciences Unit), Oliver Howes(Psychiatry Research Trust), Stephen M. Hudson, Neil Hunt(Fulbourn Hospital), Ian Jones(Genomics (United Kingdom)), I. C. MacMillan(Cumbria Northumberland Tyne and Wear NHS Foundation Trust), R. Hamish McAllister‐Williams(Cumbria Northumberland Tyne and Wear NHS Foundation Trust), DR Miklowitz, Richard Morriss(University of Nottingham), Marcus R. Munafò(University of Bristol), Carol Paton(Oxleas NHS Foundation Trust), Barbara J. Sahakian(University of Cambridge), KEA Saunders(Warneford Hospital), JMA Sinclair(University of Southampton), David Taylor(South London and Maudsley NHS Foundation Trust), Eduard Vieta(Centro de Investigación Biomédica en Red de Salud Mental), Allan H. Young(King's College London)
Journal of Psychopharmacology
March 15, 2016
Cited by 1,287Open Access
Full Text

Abstract

The British Association for Psychopharmacology guidelines specify the scope and targets of treatment for bipolar disorder. The third version is based explicitly on the available evidence and presented, like previous Clinical Practice Guidelines, as recommendations to aid clinical decision making for practitioners: it may also serve as a source of information for patients and carers, and assist audit. The recommendations are presented together with a more detailed review of the corresponding evidence. A consensus meeting, involving experts in bipolar disorder and its treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up after extensive feedback from these participants. The best evidence from randomized controlled trials and, where available, observational studies employing quasi-experimental designs was used to evaluate treatment options. The strength of recommendations has been described using the GRADE approach. The guidelines cover the diagnosis of bipolar disorder, clinical management, and strategies for the use of medicines in short-term treatment of episodes, relapse prevention and stopping treatment. The use of medication is integrated with a coherent approach to psychoeducation and behaviour change.


Related Papers